Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysisJiHoon Kang, Baek‐Yeol Ryoo, Inhwan Hwang et al.|Investigational New Drugs|2018Cited by 148
Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarkerHeejung Chae, Baek‐Yeol Ryoo, Deokhoon Kim et al.|European Journal of Cancer|2019Cited by 98
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for ResponseJunho Kang, Changhoon Yoo, Jae Ho Jeong et al.|Cancer Research and Treatment|2019Cited by 71
Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective AnalysisChanghoon Yoo, Song Cheol Kim, Sang Hyun Shin et al.|Cancers|2019Cited by 40
Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysisChanghoon Yoo, Song Cheol Kim, Sang Soo Lee et al.|British Journal of Cancer|2020Cited by 38